A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
Price : $35 *
At a glance
- Drugs Paclitaxel trevatide (Primary)
- Indications Brain metastases
- Focus Therapeutic Use
- Sponsors AngioChem
- 28 Sep 2017 Status changed from active, no longer recruiting to completed.
- 26 Apr 2017 Planned End Date changed from 1 May 2017 to 1 Oct 2017.
- 26 Apr 2017 Planned primary completion date changed from 1 May 2017 to 1 Oct 2017.